A New Zealand medicine for lung cancer, which works by disrupting the blood vessels which are within the tumor, thereby inhibiting the blood flow, seems to reflect promising results, as has been shared by researchers who are expected to reported their findings at a cancer meeting scheduled to take place in California tomorrow.

The new medicine, discovered and developed at the Auckland University and named vadimezan, when given in combination with chemotherapy, managed to extend the survival time, confirmed Associate Professor Mark McKeage, a specialist in clinical pharmacology at the university.

"Overall survival was improved numerically from a median of 8.8 to 14 months. he safety profile is favorable", he said.

The results have come after extensive studies conducted on patients suffering from advanced non-small-cell lung cancer.

The results will now be presented by Professor McKeage at the meeting "American Association for Cancer Research-International Association for the Study of Lung Cancer" in Coronado, California. The drug has been discovered by Bruce Baguley and William Denny, professors at the Auckland University.